Transforming the understanding and treatment of neurodegeneration and aging

Eti Yoles, Ph.D.

Chief Operating Officer

●●

More than 20 years of high-level experience in managing biotechnology research and development, specifically in the field of neuro-immunology. Prior to joining ImmunoBrain Checkpoint, Eti served as CSO of Immunobrain Therapies, and prior to that, as managing director of NeuroQuest and as VP of Product R&D at Proneuron Biotechnologies. Dr. Yoles holds a B.Sc. in biology, M.Sc. in physiology, and Ph.D. in neurobiology from Bar Ilan University.

Robert L. Glanzman, MD

Chief Medical Officer

●●

With over 20 years of experience in neuroscience drug development, Dr. Glanzman is a board-certified neurologist and Fellow of the American Academy of Neurology. Prior to joining industry in 1999, Dr. Glanzman held an appointment as Associate Clinical Professor of Neurology at Michigan State University. Since joining industry, Dr. Glanzman has held increasingly important leadership roles at Pfizer, Novartis and Roche, where he was responsible for the successful Phase 3 development of ocrelizumab (Ocrevus^®) for both relapsing and primary progressive Multiple Sclerosis. Prior to joining IBC, Dr. Glanzman held CMO positions at GeNeuro S.A. and Clene Nanomedicine inc.

Mr. Nathan Hevrony

Co-founder and Executive Chairman

●●

Investor with a large portfolio of holdings with 35 years of experience in private equity and merchant banking, and 22 years of experience financing and developing life science technologies. Chairman of the Board and the controlling shareholder of Babcock Power. Board member and investor in various private companies. Philanthropist.

Sharona Raveh, Ph.D.

VP Manufacturing and Product Development

●●

Over 20 years of experience in global biopharmaceutical companies, running operations and R&D teams, leading CMC and CMO activities from early phase development through commercial production. Most recently, Sharona served as Senior Director, Head of Bio-Analytical Development, CMC Biosimilars for Teva Pharmaceuticals. Prior to that Sharona served as Director of Analytical Development and CMC project manager in BTG, Ferring. Sharona holds an M.SC. from Ben-Gurion University and Ph.D from PARIS VI University and Pasteur Institute in protein engineering, structure and function.

Kuti Baruch, Ph.D.

VP Research and Development

●●

Over 10 years of biomedical research experience in the fields of neuroimmunology and therapeutic approaches to neurodegenerative conditions. During his Ph.D. studies at Prof. Schwartz’s laboratory, his research focused on brain-immune system crosstalk in neurodegenerative diseases, and targeting the peripheral immune system as a novel therapeutic approach for Alzheimer’s disease. Kuti holds a M.Sc. in Medical Science from Tel-Aviv University, and a Ph.D. in Neurobiology from the Weizmann Institute of Science.

Dalia Bracha (RN, BSN, MPA)

Head of Clinical Management and Operations

●●

An experienced clinical Project Manager with more than 20 years of demonstrated management of global clinical studies (phase I-IV) across the US, EU and Israel, having worked across large global pharmaceuticals and emerging biotech companies.

Ronit Epstein-Monin, M. Pharm, MPH

Head of Regulatory Affairs

●●

Regulatory affairs professional with over 20 years of hands-on experience in the development of innovative medicinal products. She has in-depth understanding of regulatory requirements for the development of drug-device combination products, drugs and biologics from early phase development through to phase 3 trials and subsequent NDA and MA. Ronit has worked in large biotech companies with wealth of experience in communications with the FDA and the EMA.

Alex Kertser, Ph.D.

Pipeline and Discovery Project Leader

●●

Neuroimmunologist with over 10 years of experience in pre-clinical project management, assay development and in-depth understanding of experimental animal models.
Dr. Kertser holds a B.Sc in biology and chemistry from the Hebrew University, and both M.Sc and Ph.D in Neuroimmunology from the Weizmann institute of Science.

Shai Braiman, M.Sc.

R&D scientist

●●

Over 8 years of experience biomedical research. Prior to IBC, Shai worked in Sheba Medical Center in the field of induced pluripotent stem cell (IPS). Shai holds M.Sc. in Molecular Immunology from Bar-Ilan university, focusing on immune cells signalling. Currently Shai is also an M.B.A student in the open university.

Roee Hevrony

Chief Financial Officer and Head of Business Development

●●

Prior to joining IBC in 2015, Roee worked for Babcock Power, Inc. in its nuclear power generation unit as a business controller and started his career as an investment banker with Merrill Lynch. Roee holds a bachelor’s degree in Economics from Columbia University (magna cum laude) and an MBA from the Wharton School of the University of Pennsylvania.

Tommaso Croese, MD

Medical Director

●●

Neurologist with a special focus on the contribution of immune cells in the development and progression of neurological disorders such as Multiple Sclerosis and Alzheimer’s Disease, and over 10 years of experience in preclinical models. Tommaso received his medical degree from the University of Genoa and completed his residency in neurology at San Raffaele Hospital in Milan. He is currently pursuing a PhD in neuroimmunology at the Weizmann Institute of Science.